Marc Banjak
Vermogen: 31 750 $ op 31-08-2026
Vermogen: 31 750 $ op 31-08-2026
Mr. Marc A. Banjak is a Chief Legal Officer at iBio, Inc. Mr. Banjak was previously employed as a General Counsel by Dova Pharmaceuticals, Inc., a General Counsel by Istari Oncology, Inc., and a Member by The Colorado Bar Association.
He received his undergraduate degree from Franklin & Marshall College and a graduate degree from Sturm College of Law.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IBIO, INC. 0,07% | 01-09-2026 | 25.000 ( 0,07% ) | 31 750 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| IBIO, INC. | Algemeen Adviseur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Algemeen Adviseur | 01-04-2021 |
The Colorado Bar Association | Corporate Officer/Principal | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Comptroller/Controller/Auditor | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 6 |
|---|---|
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado Bar Association | |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Sturm College of Law
Sturm College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau